Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on November 19th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on October 27th. The trade occurred in the Representative's "STATE STREET BANK & TRUST CO." account.
Representative Thomas H. Kean, Jr. also recently made the following trade(s):
- Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 10/27/2026.
- Sold $1,001 - $15,000 in shares of Stryker NYSE: SYK on 10/27/2026.
- Sold $1,001 - $15,000 in shares of Warner Bros. Discovery NASDAQ: WBD on 10/7/2026.
- Sold $1,001 - $15,000 in shares of Stryker NYSE: SYK on 9/30/2026.
- Sold $1,001 - $15,000 in shares of Johnson & Johnson NYSE: JNJ on 9/30/2026.
- Purchased $1,001 - $15,000 in shares of ESAB NYSE: ESAB on 9/29/2026.
- Sold $1,001 - $15,000 in shares of Mondelez International NASDAQ: MDLZ on 9/23/2026.
- Sold $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 9/17/2026.
- Purchased $1,001 - $15,000 in shares of Texas Instruments NASDAQ: TXN on 9/17/2026.
- Sold $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOGL on 8/27/2026.
Johnson & Johnson Stock Down 2.1%
Shares of Johnson & Johnson stock opened at $267.02 on Friday. Johnson & Johnson has a 1 year low of $199.90 and a 1 year high of $290.25. The company has a market cap of $642.80 billion, a P/E ratio of 40.46, a P/E/G ratio of 2.74 and a beta of 0.22. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The stock has a 50-day moving average price of $267.43 and a 200 day moving average price of $250.79.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to analysts' expectations of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The business's revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts expect that Johnson & Johnson will post 11.12 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio is currently 81.21%.
Analyst Ratings Changes
JNJ has been the subject of a number of research reports. Erste Group Bank lowered shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Wednesday, October 21st. TD Cowen reaffirmed a "buy" rating on shares of Johnson & Johnson in a research report on Tuesday, October 20th. Wall Street Zen downgraded Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Morgan Stanley reduced their price target on Johnson & Johnson from $294.00 to $292.00 and set an "overweight" rating for the company in a report on Thursday, October 15th. Finally, Royal Bank Of Canada lowered their price target on Johnson & Johnson from $290.00 to $280.00 and set an "outperform" rating for the company in a research note on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $275.92.
Get Our Latest Stock Report on JNJ
Johnson & Johnson News Roundup
These are some of the JNJ news items that stood out recently:
- Positive Sentiment: Prostate cancer data presented at ESMO were described as “immaculate,” suggesting Johnson & Johnson’s $3.05 billion Halda acquisition is showing clinical promise. The data could strengthen the company’s oncology pipeline, though the program remains subject to further development. Article
- Positive Sentiment: Johnson & Johnson filed for FDA approval to expand CAPLYTA to bipolar I mania or mixed episodes. Two Phase 3 studies showed symptom improvement versus placebo; approval would add a potential fifth adult indication, but remains uncertain. Article
- Negative Sentiment: A Louisiana appeals court upheld a multimillion-dollar talc verdict and an increase in damages, adding to potential legal costs and uncertainty. Separately, Pomerantz LLP announced an investigation into investor claims; the announcement is not a finding of wrongdoing. Appeal ruling article Investor investigation notice
Institutional Investors Weigh In On Johnson & Johnson
Several institutional investors and hedge funds have recently added to or reduced their stakes in JNJ. CKW Financial Group increased its holdings in Johnson & Johnson by 0.9% in the 3rd quarter. CKW Financial Group now owns 4,269 shares of the company's stock valued at $1,104,000 after buying an additional 37 shares during the period. Silver Coast Investments LLC lifted its holdings in shares of Johnson & Johnson by 3.8% during the 2nd quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock worth $271,000 after acquiring an additional 39 shares during the period. Townsend Asset Management Corp NC ADV lifted its holdings in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock worth $1,630,000 after acquiring an additional 39 shares during the period. Triumph Capital Management lifted its holdings in shares of Johnson & Johnson by 1.6% during the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company's stock worth $643,000 after acquiring an additional 39 shares during the period. Finally, Kwmg LLC boosted its position in shares of Johnson & Johnson by 1.7% during the 3rd quarter. Kwmg LLC now owns 2,383 shares of the company's stock valued at $631,000 after acquiring an additional 39 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the firm's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Elizabeth Forminard sold 13,072 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total value of $3,717,546.08. Following the sale, the executive vice president directly owned 16,994 shares in the company, valued at $4,832,923.66. The trade was a 43.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.16% of the company's stock.
About Representative Kean
Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey's 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.
Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey's 7th Congressional District. He declared candidacy for the 2026 election.
Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.